

817 **Table I.** Summary of Systematic Reviews and Meta-Analyses Assessing the Association Between Psoriasis and Major Adverse  
 818 Cardiovascular Events.

| Study                                | Study Dates                       | Number of Studies | Total Number of Patients                  |              | Outcome                           | Composite Measure of Association (95% CI) |                  |
|--------------------------------------|-----------------------------------|-------------------|---|--------------|-----------------------------------|---|------------------|
|                                      |                                   |                   | Psoriasis                                 | No Psoriasis |                                   | Mild                                      | Severe           |
| Armstrong, et al. <sup>19</sup> 2013 | January 1, 1980 – January 1, 2012 | 9                 | Mild:<br>201,239<br><br>Severe:<br>17,415 | 9,914,799    | MACE: MI, stroke,<br>CV mortality | MI  |                  |
|                                      |                                   |                   |   |              |                                   | RR  | RR               |
|                                      |                                   |                   |   |              |                                   | 1.29 (1.02-1.63)                          | 1.70 (1.32-2.18) |
|                                      |                                   |                   |   |              |                                   | Stroke                                    |                  |
|                                      |                                   |                   |   |              |                                   | RR  | RR               |
|                                      |                                   |                   |   |              |                                   | 1.12 (1.08-1.16)                          | 1.56 (1.32-1.84) |

|  |  |  |  |  |  | CV Mortality     |                  |
|--|--|--|--|--|--|------------------|------------------|
|  |  |  |  |  |  | RR               | RR               |
|  |  |  |  |  |  | 1.03 (0.86-1.25) | 1.39 (1.11-1.74) |
| Gaeta, et al. <sup>20</sup><br>2013            |  |  |  |  |  | Overall CV Risk  |                  |
|  |  |  |  |  |  | RR               |                  |
|  |  |  |  |  |  | 1.24 (1.18-1.31) |                  |
|  |  |  |  |  |  | MI               |                  |
|  |  |  |  |  |  | RR               |                  |
|  |  |  |  |  |  | 1.24 (1.11-1.39) |                  |
| CV risk: MI,<br>vascular disease,<br>mortality |  |  |  |  |  | Vascular Disease |                  |
|  |  |  |  |  |  | RR               |                  |
|  |  |  |  |  |  | 1.27 (1.12-1.43) |                  |
|  |  |  |  |  |  |                  |                  |
|  |  |  |  |  |  |                  |                  |

|                                  |                           |    |  |              |                  |
|----------------------------------|---------------------------|----|--|--------------|------------------|
|                                  |                           |    |  |              | Mortality        |
|                                  |                           |    |  |              | RR               |
|                                  |                           |    |  |              | 1.41 (0.97-2.04) |
|                                  |                           |    |  |              | MI               |
|                                  |                           |    |  |              | RR               |
|                                  |                           |    |  |              | 1.32 (1.13-1.55) |
|                                  |                           |    |  |              | Stroke           |
|                                  |                           |    |  |              | RR               |
|                                  |                           |    |  |              | 1.26 (1.12-1.41) |
|                                  |                           |    |  |              | CVD              |
|                                  |                           |    |  |              | RR               |
|                                  |                           |    |  |              | 1.47 (1.30-1.60) |
| Gu, et al. <sup>21</sup><br>2013 | 1966 –<br>October<br>2012 | 15 | Total (psoriasis + no<br>psoriasis): 6,230,774 | MI           |                  |
|                                  |                           |    |  | Stroke       |                  |
|                                  |                           |    |  | CVD          |                  |
|                                  |                           |    |  | CV mortality |                  |
|                                  |                           |    |  |              |                  |
|                                  |                           |    |  |              |                  |

|                                       |                           |    |         |           |                     |                                   |
|---------------------------------------|---------------------------|----|---------|-----------|---------------------|-----------------------------------|
|                                       |                           |    |         |           |                     | CV mortality                      |
|                                       |                           |    |         |           |                     | RR                                |
|                                       |                           |    |         |           |                     | 1.33 (1.00-1.77)                  |
| Horreau, et<br>al. <sup>22</sup> 2013 | 1980 –<br>December<br>211 | 33 | 324,650 | 5,309,087 | MI<br>CAD<br>Stroke | MI                                |
|                                       |                           |    |         |           |                     | RR                                |
|                                       |                           |    |         |           |                     | Cohort: 1.25 (1.03, 1.52)         |
|                                       |                           |    |         |           |                     | Cross-sectional: 1.57 (1.08-2.27) |
|                                       |                           |    |         |           |                     | CAD                               |
|                                       |                           |    |         |           |                     | RR                                |
|                                       |                           |    |         |           |                     | Cohort: 1.20 (1.13, 1.27)         |
|                                       |                           |    |         |           |                     | Case-control: 1.84 (1.09-3.09)    |
|                                       |                           |    |         |           |                     | Cross-sectional: 1.19 (1.14-1.24) |



|   |             |    |  |            |   |  |   |  |
|---|-------------|----|--|------------|---|--|---|--|
|   |             |    |  |            |   |  | 0.9 (0.4-2.2)                                     |  |
| Pietrzak, et al. <sup>24</sup> 2013     | 1960 – 2011 | 14 | 367,358  | 9,199,656  | CV events (MI, IHD, cerebral ischemic stroke, sudden cardiac death) |  | OR 1.28 (1.18-1.38)                               |  |
| Samarasekera, et al. <sup>25</sup> 2013 | 1974 – 2012 | 14 | All:<br>488,315<br><br>Mild:<br>327,418<br><br>Severe: | 10,024,815 | MI<br><br>Stroke<br><br>CV mortality                                | All<br><br>MI<br><br>HR/IRR<br><br>1.40<br><br>(1.03-1.89) | Mild<br><br>HR/IRR<br><br>1.34<br><br>(1.07-1.68) | Severe<br><br>HR/IRR<br><br>3.04<br><br>(0.65-14.35) |
|   |             |    |  |            | Stroke  |  |   |  |
|   |             |    |  |            |   | HR/IRR   | HR/IRR  | HR/IRR   |

|                                  |                                  |   |         |           |                             |                        |                            |   |
|----------------------------------|----------------------------------|---|---------|-----------|-----------------------------|------------------------|----------------------------|---|
|                                  |                                  |   | 12,854  |           |                             | 1.13<br>(1.01-1.26)    | 1.15<br>(0.98-1.35)        | 1.59<br>(1.34-1.89)                                     |
| CV Mortality                     |                                  |   |         |           |                             |                        |                            |   |
|                                  |                                  |   |         |           |                             | NR                     | SMR<br>1.03<br>(0.86-1.25) | SMR<br>1.37<br>(1.17-1.60)<br>HR<br>1.57<br>(1.26-1.96) |
|                                  |                                  |   |         |           |                             |                        |                            |   |
| Xu, et al. <sup>26</sup><br>2012 | Database<br>inception<br>– March | 7 | 326,598 | 5,230,048 | Composite of MI &<br>stroke | Composite              |                            |   |
|                                  |                                  |   |         |           |                             | RR<br>1.20 (1.10-1.31) |                            |   |

|  |      |  |        |                  |    |    |
|--|------|--|--------|------------------|----|----|
|  | 2012 |  |        |                  |    | MI |
|  |      |  |        |                  | RR |    |
|  |      |  |        | 1.22 (1.05-1.42) |    |    |
|  |      |  | Stroke |                  |    |    |
|  |      |  |        | RR               |    |    |
|  |      |  |        | 1.21 (1.04-1.40) |    |    |

819

820 CAD, coronary artery disease; CHD, coronary heart disease; CV, cardiovascular; CVD, cardiovascular disease; HR, hazard ratio;  
 821 IHD, ischemic heart disease; IRR, incidence rate ratio; MACE, major adverse cardiovascular event; MI, myocardial infarction; OR,  
 822 odds ratio; RR, relative risk or risk ratio

823 <sup>a</sup>Systematic review and meta-analysis of the association between psoriasis and cardiovascular disease and cardiovascular risk factors.  
 824 Total numbers of studies and patients included are as reported in the full systematic review and meta-analysis, a subset of which is  
 825 specifically relevant to psoriasis and cardiovascular disease.